Aktienanalyse zu Codexis, Inc. (CDXS)CDXSCodexis, Inc.

Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing. It operates in the Healthcare sector (INDUSTRIAL ORGANIC CHEMICALS industry).

Codexis Inc is not a good buy right now due to its current price of $1.045, which is significantly below its 52-week high of $2.98, and an RSI of 16.59 indicating it is oversold. The company has also reported a net loss of $12 million in Q2 2026, and insider selling has increased by 150.31% over the last month, suggesting a lack of confidence from insiders.

4 analysts cover CDXS: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 6.00.